Transformative Biotech

Kevin Kraus, CEO
kevin@transformative-bio.com
+1 (720) 329-3455
3780 23rd Street, Boulder, CO 80304
www.transformative-bio.com

Transforming PCR Testing for Infectious Diseases @ANYWHERE™

LEADERSHIP TEAM

EXTENSIVE DIAGNOSTIC EXPERIENCE

Kevin Kraus, MBA
Chief Executive Officer

Mark Kelleher, PhD, MBA
EVP, Research & Development

Nicholas Meyerson, PhD
VP, Product Strategy & Partnerships

Shelle Pourmanafzadehardabili
VP, Business Operations

BOARD OF DIRECTORS

Barbara Handelin, PhD
Board Member, pioneer in PCR

Russ Hullet
Co-Founder, Board Director

Bob Blomquist
Co-Inventor, Board Chair

KEY ADVISORS

Chuck Henry, PhD
Professor of Engineering, CSU

Tony Shuber
Diagnostics Advisor & Sr. Executive

Mickey Urdea, PhD
Diagnostics Advisor & pioneer

INTELLECTUAL PROPERTY

- Landmark US Patent 12,344,889 issued July 2025
- US Patent 12,680,130 issued July 2026
- Broad patent estate with 5 additional patents pending

ASK / USE OF FUNDS

$500k bridge now
$6M equity in 2027


- Complete DirectAmp evaluations
- Launch RUO & grow sales
- Advance IVD collection kit
- Build commercial partnerships
- Fund IP & operations

PROBLEM

- 14M people die annually from infectious diseases like tuberculosis, respiratory infections, and sexually transmitted infections (STIs).
- People lack access to rapid, accurate & affordable PCR testing.
- PCR is the gold standard for detecting infections, but testing remains complex, costly, and dependent on skilled lab techs.

OUR SOLUTIONS

- Our patented DirectAmp™ chemistries eliminate nucleic acid extraction, enabling simpler and more affordable PCR testing.



Direct-to-PCR improvement vs. conventional PCR:
Faster (5-14x) - Lower cost - Less hands-on time

CLINICALLY VALIDATED

- >590,000 patients tested for SARS-CoV-2 using technologies developed by predecessor company, Summit Biolabs.
- Demonstrated 99% agreement with conventional PCR.
- ≥ 7-day sample stability at 40°C (swab & saliva).
- Proof-of-concept: viruses (Flu+COVID) and bacteria (STIs chlamydia, gonorrhea) with further studies planned on challenging pathogens (e.g., tuberculosis).

TARGET MARKET OPPORTUNITY

- $17B global molecular diagnostics target market (labs and manufacturers), spanning reagents, sample collection, and lab and point-of-care PCR.
- Establish partnerships for platform technologies, including @ANYWHERE™ device, for sales & licensing opportunities.
- Drive DirectAmp™ reagent sales beginning with RUO, then IVD through partners & distributors.
- Engaged with 10+ potential lab and diagnostic partners, with several exploring evaluations of DirectAmp™.

IMPACT

- Change the future of PCR diagnostics for infectious diseases to expand access, reduce the spread of disease, and ultimately save lives.